Home Clinical Topics Drugs and Devices FDA expands approved use of Kalydeco for CF

FDA expands approved use of Kalydeco for CF

On May 17, the U.S. Food and Drug Administration (FDA) expanded the approved use of Kalydeco (ivacaftor) for treating cystic fibrosis (CF), tripling the number of rage gene mutations the drug can now treat. Read more

LEAVE A REPLY

Please enter your comment!
Please enter your name here